Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
ImmuCell Corporation is a biotechnology business based in the US. ImmuCell Corporation shares (ICCC) are listed on the NASDAQ and all prices are listed in US Dollars. ImmuCell Corporation employs 61 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$8.91|
|52-week range||$5.21 - $12.09|
|50-day moving average||$9.32|
|200-day moving average||$9.58|
|Wall St. target price||$14.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.06|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-3.99%|
|1 month (2021-09-24)||-8.05%|
|3 months (2021-07-23)||-12.99%|
|6 months (2021-04-23)||-16.34%|
|1 year (2020-10-23)||56.32%|
|2 years (2019-10-23)||68.12%|
|3 years (2018-10-23)||5.57%|
|5 years (2016-10-21)||48.50%|
Valuing ImmuCell Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ImmuCell Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ImmuCell Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.4 million.
The EBITDA is a measure of a ImmuCell Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$16.1 million|
|Gross profit TTM||$6.9 million|
|Return on assets TTM||-1.55%|
|Return on equity TTM||-1.43%|
|Market capitalisation||$71.8 million|
TTM: trailing 12 months
There are currently 10,422 ImmuCell Corporation shares held short by investors – that's known as ImmuCell Corporation's "short interest". This figure is 3.1% down from 10,760 last month.
There are a few different ways that this level of interest in shorting ImmuCell Corporation shares can be evaluated.
ImmuCell Corporation's "short interest ratio" (SIR) is the quantity of ImmuCell Corporation shares currently shorted divided by the average quantity of ImmuCell Corporation shares traded daily (recently around 9223.0088495575). ImmuCell Corporation's SIR currently stands at 1.13. In other words for every 100,000 ImmuCell Corporation shares traded daily on the market, roughly 1130 shares are currently held short.
However ImmuCell Corporation's short interest can also be evaluated against the total number of ImmuCell Corporation shares, or, against the total number of tradable ImmuCell Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ImmuCell Corporation's short interest could be expressed as 0% of the outstanding shares (for every 100,000 ImmuCell Corporation shares in existence, roughly 0 shares are currently held short) or 0.0019% of the tradable shares (for every 100,000 tradable ImmuCell Corporation shares, roughly 2 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ImmuCell Corporation.
Find out more about how you can short ImmuCell Corporation stock.
We're not expecting ImmuCell Corporation to pay a dividend over the next 12 months.
ImmuCell Corporation's shares were split on a 1:100 basis on 24 July 1990. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ImmuCell Corporation shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for ImmuCell Corporation shares which in turn could have impacted ImmuCell Corporation's share price.
Over the last 12 months, ImmuCell Corporation's shares have ranged in value from as little as $5.21 up to $12.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmuCell Corporation's is 0.8709. This would suggest that ImmuCell Corporation's shares are less volatile than average (for this exchange).
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Steps to owning and managing Valkyrie Bitcoin Strategy ETF units.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Oct. 21, 2021
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.